CD8A and cancer: We confirmed that the number and activity of CD8+ and CD4+ T cells in tumors and DLNs of the 4T1-bearing immunocompetent model were both increased by the combined administration of TEM and anti-PD-L1 antibodies, thereby exhibiting anti-cancer effects.